Literature DB >> 22429719

A mouse model of tuberculosis reinfection.

Marcela Henao-Tamayo1, Andrés Obregón-Henao, Diane J Ordway, Shaobin Shang, Colleen G Duncan, Ian M Orme.   

Abstract

Recent clinical observations shows that individuals treated with chemotherapy for tuberculosis who live in endemic areas are four times more likely to develop secondary disease, often as not caused by exogenous reinfection. In a mouse model described here, we show that mice infected with the virulent W-Beijing Mycobacterium tuberculosis strain HN878, then given chemotherapy to clear the infection, were resistant to re-challenge with the same organism thereafter. This resistance, which was mediated by rapid expression of CD4 T cells expressing markers consistent with both central and effector memory immunity, was only transient however. After 20-30 days of the reinfection the numbers of these cells steadily declined, the bacterial load in the lungs surged up, and the lung tissues became increasingly consolidated. No evidence was found for a regulatory T cell response in these mice, but many T cells harvested from the lungs showed evidence of increased PD-1 expression, indicating exhaustion. These data indicate that the memory T cell response to reinfection may not be as stable and long lived as previously thought, a finding with obvious implications for vaccine development.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22429719     DOI: 10.1016/j.tube.2012.02.008

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  15 in total

1.  Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.

Authors:  Marcela Henao-Tamayo; Andrés Obregón-Henao; Elizabeth Creissen; Crystal Shanley; Ian Orme; Diane J Ordway
Journal:  Clin Vaccine Immunol       Date:  2014-11-12

Review 2.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

3.  A new unifying theory of the pathogenesis of tuberculosis.

Authors:  Ian M Orme
Journal:  Tuberculosis (Edinb)       Date:  2013-08-04       Impact factor: 3.131

Review 4.  Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control.

Authors:  Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

5.  Effect of bacillus Calmette-Guérin vaccination on CD4+Foxp3+ T cells during acquired immune response to Mycobacterium tuberculosis infection.

Authors:  Marcela I Henao-Tamayo; Andres Obregón-Henao; Kimberly Arnett; Crystal A Shanley; Brendan Podell; Ian M Orme; Diane J Ordway
Journal:  J Leukoc Biol       Date:  2015-11-20       Impact factor: 4.962

6.  B Cells and Programmed Death-Ligand 2 Signaling Are Required for Maximal Interferon-γ Recall Response by Splenic CD4⁺ Memory T Cells of Mice Vaccinated with Mycobacterium tuberculosis Ag85B.

Authors:  Antonella Riccomi; Carla Palma
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

7.  Immune requirements for protective Th17 recall responses to Mycobacterium tuberculosis challenge.

Authors:  L Monin; K L Griffiths; S Slight; Y Lin; J Rangel-Moreno; S A Khader
Journal:  Mucosal Immunol       Date:  2015-01-28       Impact factor: 7.313

8.  Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4(+) T cells but no increase in avidity for Ag85A.

Authors:  Hannah J Metcalfe; Sabine Steinbach; Gareth J Jones; Tim Connelley; W Ivan Morrison; Martin Vordermeier; Bernardo Villarreal-Ramos
Journal:  Vaccine       Date:  2016-08-04       Impact factor: 3.641

9.  Modeling the spread of tuberculosis in semiclosed communities.

Authors:  Mauricio Herrera; Paul Bosch; Manuel Nájera; Ximena Aguilera
Journal:  Comput Math Methods Med       Date:  2013-05-09       Impact factor: 2.238

10.  Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.

Authors:  Rolf Billeskov; Jan P Christensen; Claus Aagaard; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.